Biopharma | June 26, 2026
Moderna outlines aggressive multi-modal growth strategy
The company emphasized that its mRNA system is built on three pillars—mRNA science, delivery science, and manufacturing processes
The company emphasized that its mRNA system is built on three pillars—mRNA science, delivery science, and manufacturing processes
The backing comes as influenza remains a persistent public health burden
Highlights India’s advances in pharmacopoeial science, regulatory standards, and global harmonization efforts at the 16th International Meeting of World Pharmacopoeias
CEO Stéphane Bancel framed the changes as essential to scaling the business
Pharma industry veteran brings more than two decades of experience in sales, marketing, business development, and global market expansion to his new leadership role
Healthcare industry leader returns to India to support Apollo Hospitals’ global expansion and advance the ‘Heal in India, Heal by India’ vision
Day-care model aimed at providing specialized psychological support for women during pregnancy and motherhood
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
The conference highlighted research suggesting that deuterium levels may influence key biological processes
Subscribe To Our Newsletter & Stay Updated
